Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma

Neoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines. Interim data from our clinical study NCT03715985 showed that the personalized peptide-based neoantigen vaccine EVX-01, formulated in the liposomal adjuvant, CAF09b, was safe and able to elicit EVX-01-specific T cell responses in patients with metastatic melanoma. Here, we present results from the dose-escalation part of the study, evaluating the feasibility, safety, efficacy, and immunogenicity of EVX-01 in addition to anti-PD-1 therapy.

Publication: Journal for ImmunoTherapy of Cancer

By: Sofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri,  Arianna Draghi , Kalijn Bol , Mohammad Kadivar, Marie Christine Wulff Westergaard, Joachim Stoltenborg Granhøj, Annie Borch, Nadia Viborg Petersen, Nikolas Thuesen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Rebecca Bach Dohn, Christina Westmose Yde, Nis Noergaard, Torben Lorentzen, Anders Bundgaard Soerensen, Daniela Kleine-Kohlbrecher, Anders Jespersen, Dennis Christensen, Jens Kringelum, Marco Donia, Sine Reker Hadrup, nge Marie Svane